Literature DB >> 21249669

Medical methods for mid-trimester termination of pregnancy.

Hajo Wildschut1, Marieke I Both, Suzanne Medema, Eeke Thomee, Mark F Wildhagen, Nathalie Kapp.   

Abstract

BACKGROUND: With the improvement of ultrasound technology, the likelihood of detection of major fetal structural anomalies in mid-pregnancy has increased considerably. Upon the detection of serious anomalies, women typically are offered the option of pregnancy termination. Additionally, there are still many reasons other than fetal anomalies why women seek abortion in the mid-trimester.
OBJECTIVES: To compare different methods of second trimester medical termination of pregnancy for their efficacy and side-effects. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, Popline and reference lists of retrieved papers and other sources. SELECTION CRITERIA: All randomised controlled trials (RCTs) examining medical regimens for termination of pregnancy of a singleton living fetus between 12-28 weeks' gestation were analysed. The outcome measures were the induction to abortion interval, abortion rate within 24 hours, need for surgical evacuation, blood loss, uterine rupture, pain, and side-effects.Trials including >20% fetal death, multiple pregnancies, previous uterine scars and regimens which involved cervical preparation were excluded. DATA COLLECTION AND ANALYSIS: Two authors selected the trials and three authors extracted data. MAIN
RESULTS: Fourty RCTs were included, addressing various agents for pregnancy termination and methods of administration. When used alone, misoprostol was an effective inductive agent, though it appeared to be more effective in combination with mifepristone. However, the evidence from RCTs is limited.Misoprostol was preferably administered vaginally, although among multiparous women sublingual administration appeared equally effective. A range of doses of vaginally administered misoprostol has been used. No randomised trials comparing doses of misoprostol were identified; however low doses of misoprostol appear to be associated with fewer side-effects while moderate doses appear to be more efficient in completing abortion. Four RCTs showed that the induction to abortion interval with 3-hourly vaginal administration of prostaglandins is shorter than 6-hourly administration without an increase in side-effects.Many studies reported the need for surgical evacuation. Indications for surgical evacuation include retained products of the placenta and heavy vaginal bleeding. Fewer women required surgical evacuation when misoprostol was administrated vaginally compared with women receiving intra-amniotical PGF(2a) . Mild, self-limiting diarrhoea was more common among women who received misoprostol compared to other agents. AUTHORS'
CONCLUSIONS: Medical abortion in the second trimester using the combination of mifepristone and misoprostol appeared to have the highest efficacy and shortest abortion time interval. Where mifepristone is not available, misoprostol alone is a reasonable alternative. The optimal route for administering misoprostol is vaginally, preferably using tablets at 3-hourly intervals. Apart from pain, the side-effects of vaginal misoprostol are usually mild and self limiting. Conclusions from this review are limited by the gestational age ranges and variable medical regimens, including dosing, administrative routes and intervals of medication, of the included trials.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21249669      PMCID: PMC8557267          DOI: 10.1002/14651858.CD005216.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  117 in total

1.  Medical abortion in women of less than or equal to 56 days amenorrhoea: a comparison between gemeprost (a PGE1 analogue) alone and mifepristone and gemeprost.

Authors:  J E Norman; K J Thong; M W Rodger; D T Baird
Journal:  Br J Obstet Gynaecol       Date:  1992-07

2.  Vaginal vs. oral misoprostol for mid-trimester abortion.

Authors:  A Nigam; V K Singh; A Prakash
Journal:  Int J Gynaecol Obstet       Date:  2006-01-23       Impact factor: 3.561

3.  A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality.

Authors:  Jan E Dickinson; Sharon F Evans
Journal:  Obstet Gynecol       Date:  2003-06       Impact factor: 7.661

4.  An historical overview of second trimester abortion methods.

Authors:  Marc Bygdeman; Kristina Gemzell-Danielsson
Journal:  Reprod Health Matters       Date:  2008-05

5.  Absorption kinetics of misoprostol with oral or vaginal administration.

Authors:  M Zieman; S K Fong; N L Benowitz; D Banskter; P D Darney
Journal:  Obstet Gynecol       Date:  1997-07       Impact factor: 7.661

6.  A randomized trial of 2 regimens for the administration of vaginal prostaglandins (gemeprost) for the induction of midtrimester abortion.

Authors:  R J Armatage; M J Luckas
Journal:  Aust N Z J Obstet Gynaecol       Date:  1996-08       Impact factor: 2.100

7.  Termination of second trimester pregnancy with sulprostone and mifepristone: a randomized double-blind placebo-controlled trial.

Authors:  P C Ho; H K Ma
Journal:  Contraception       Date:  1993-02       Impact factor: 3.375

8.  Abortion during mid-pregnancy by rivanol-catheter supplemented with PGF2 alpha drip-infusion or quinine hydrocholoride.

Authors:  Y Manabe; A Manabe
Journal:  Contraception       Date:  1981-06       Impact factor: 3.375

9.  The vaginal administration of 9-deoxo-16,16-dimethyl-9-methylene PGE2 for second trimester abortion.

Authors:  C A Ballard
Journal:  Contraception       Date:  1981-08       Impact factor: 3.375

10.  Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome.

Authors:  P A Boyd; C Devigan; B Khoshnood; M Loane; E Garne; H Dolk
Journal:  BJOG       Date:  2008-05       Impact factor: 6.531

View more
  20 in total

Review 1.  Role of nuclear progesterone receptor isoforms in uterine pathophysiology.

Authors:  Bansari Patel; Sonia Elguero; Suruchi Thakore; Wissam Dahoud; Mohamed Bedaiwy; Sam Mesiano
Journal:  Hum Reprod Update       Date:  2014-11-18       Impact factor: 15.610

2.  Buccal versus vaginal misoprostol administration for the induction of first and second trimester abortions.

Authors:  Geetika Garg; Navneet Takkar; Alka Sehgal
Journal:  J Obstet Gynaecol India       Date:  2014-10-31

3.  Comparison of Effectiveness of Sublingual and Vaginal Misoprostol for Second-Trimester Abortion.

Authors:  Alka A Mukherjee
Journal:  J Obstet Gynaecol India       Date:  2018-12-04

4.  A Comparative Study of Misoprostol Only and Mifepristone Plus Misoprostol in Second Trimester Termination of Pregnancy.

Authors:  Prasanna Latha Akkenapally
Journal:  J Obstet Gynaecol India       Date:  2016-04-13

5.  Influence of Mifepristone in Induction Time for Terminations in the Second and Third Trimester.

Authors:  M Hoopmann; J Hirneth; J Pauluschke-Fröhlich; B Yazdi; H Abele; D Wallwiener; K O Kagan
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-03-28       Impact factor: 2.915

6.  Mifepristone Followed by Misoprostol or Ethacridine Lactate and Oxytocin for Second Trimester Abortion: A Randomized Trial.

Authors:  Vatsla Dadhwal; Sita Garimella; Kavita Khoiwal; K Aparna Sharma; Vanamail Perumal; Dipika Deka
Journal:  Eurasian J Med       Date:  2019-08-19

Review 7.  Medical treatments for incomplete miscarriage.

Authors:  Caron Kim; Sharmani Barnard; James P Neilson; Martha Hickey; Juan C Vazquez; Lixia Dou
Journal:  Cochrane Database Syst Rev       Date:  2017-01-31

Review 8.  Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death.

Authors:  Jodie M Dodd; Caroline A Crowther
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

9.  Implementation of misoprostol for postabortion care in Kenya and Uganda: a qualitative evaluation.

Authors:  Joachim Osur; Traci L Baird; Brooke A Levandowski; Emily Jackson; Daniel Murokora
Journal:  Glob Health Action       Date:  2013-04-24       Impact factor: 2.640

10.  Comparison of sublingual and vaginal misoprostol for second-trimester pregnancy terminations.

Authors:  Forozan Milani; Seyede Hajar Sharami; Saeedeh Arjmandi
Journal:  J Family Reprod Health       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.